China's First DAC Drug Goes Global: Hezheng Pharma Announces Landmark Overseas Partnership
Johnson & Johnson
Medical Device R&D and Manufacturer
2026Year1Month26Day,Hangzhou Hezheng Pharmaceutical Co., Ltd. announced a collaboration with a U.S. biotechnology company on Targeted Protein Degradation Antibody Conjugates (DAC) Global partnership for drugs.According to the agreement, Hezheng Pharmaceutical will retain the cooperation.DACThe Greater China rights to the drug, and will receive an upfront payment, milestone payments, sales royalties, and potential sublicensing revenue. This is a biopharmaceutical company in China.DACThis first overseas collaboration deal in this cutting-edge field is not only an important milestone in the company's development journey but also a strong testament to the rising influence of Chinese pharmaceutical enterprises on the global stage of drug innovation.
This collaboration also follows2025At the beginning of the year, the company announced that it had reached an agreement with Johnson & JohnsonBTKAfter the degradation agent's overseas collaboration, in targeted protein degradation (TPD) The second overseas licensing collaboration in this field demonstrates the company's strong competitiveness and innovation capabilities. Further details of this collaboration will be disclosed at a time agreed upon by both parties.
Hepharma is a clinical-stage small molecule innovative drug development company driven by innovation technology, committed to addressing unmet clinical needs. The company independently develops targeted protein degradation drugs and an intelligent drug discovery platform, focusing on drug research and development in the fields of oncology, autoimmune diseases, and central nervous system disorders. Hepharma has established a pipeline comprising more than 10 novel drug candidates, with six molecules currently in clinical trials, two molecules in pivotal registrational studies, and one molecule granted Breakthrough Therapy Designation. Additionally, the company has completed six new drug pipeline collaborations with renowned pharmaceutical companies both in China and globally, including Johnson & Johnson, earning widespread recognition for its drug discovery and development capabilities within the industry.